$231 Million

Black Diamond Therapeutics, Inc.

Initial Public Offering

Bookrunner, January 2020

Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a precision oncology medicine company discovering and developing small molecule targeted oncology therapies for genetically defined patients. The Company’s pipeline targets families of non-classical mutations outside the active site, like allosteric mutations, as well as other groups of activating mutations of ErbB kinase targets.